Lebrikizumab
Lebrikizumab
Lebrikizumab (pronounced leb-ri-ki-zu-mab) is a monoclonal antibody designed for the treatment of asthma and other inflammatory diseases. It is currently under development by Roche and Genentech.
Etymology
The name "Lebrikizumab" is derived from the International Nonproprietary Names (INN), where "zu" refers to humanized antibody, "mab" refers to monoclonal antibody, and "lebriki" is a unique stem.
Mechanism of Action
Lebrikizumab works by targeting and neutralizing interleukin-13 (IL-13), a cytokine involved in inflammatory responses. By blocking IL-13, lebrikizumab can reduce inflammation and improve symptoms in diseases where IL-13 plays a key role.
Clinical Trials
Lebrikizumab has been tested in several clinical trials for its efficacy and safety in treating asthma and atopic dermatitis. The results have shown promise, but further research is needed to fully understand its potential benefits and risks.
Related Terms
External links
- Medical encyclopedia article on Lebrikizumab
- Wikipedia's article - Lebrikizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski